Page last updated: 2024-08-25

bexarotene and cd 3254

bexarotene has been researched along with cd 3254 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
di Martino, O; Ivan, DJ; Jurutka, PW; Khadka, I; Krall, TD; Le, A; Lee, IJ; Lee, MY; Liu, W; Mallick, S; Marshall, PA; Moen, GA; Noh, Y; Peoples, SJ; Perez, A; Petros, R; Reshi, S; Salama, E; Salama, J; Sausedo, MA; Savage, BM; Tromba, L; Wagner, CE; Welch, JS; Ziller, JW	1

Other Studies

1 other study(ies) available for bexarotene and cd 3254

Article	Year
An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene. International journal of molecular sciences, 2022, Dec-19, Volume: 23, Issue:24 Topics: Bexarotene; Humans; Leukemia; Liver X Receptors; Lymphoma, T-Cell, Cutaneous; Retinoid X Receptors; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Triglycerides	2022

Article

Year

An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.

International journal of molecular sciences, 2022, Dec-19, Volume: 23, Issue:24

Topics: Bexarotene; Humans; Leukemia; Liver X Receptors; Lymphoma, T-Cell, Cutaneous; Retinoid X Receptors; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Triglycerides

2022